{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"15.7","upperLimit":"84.3","value":"50.0"},{"groupId":"OG001","lowerLimit":"16.3","upperLimit":"67.7","value":"40.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"15"}],"units":"Participants"}],"description":"ORR was defined as the percentage of participants with the best overall confirmed response of complete response (CR) or partial response (PR) according to the appropriate response assessment criteria including Response Evaluation Criteria in Solid Tumors (RECIST 1.1) or Response Assessment in Neuro-Oncology (RANO) for the disease setting as assessed by the Investigator. CR or PR was confirmed at a subsequent scan (\\>=4 weeks) if the criteria for each are met . The exact 95% confidence intervals (CIs) were calculated using Clopper-Pearson method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Adult participants (≥ 18 years) were administered Tovorafenib 600 mg orally (PO) once weekly (QW).","id":"OG000","title":"Melanoma Cohort"},{"description":"Adult participants (≥ 18 years) were administered Tovorafenib 600 mg PO QW.","id":"OG001","title":"Tissue Agnostic Cohort"}],"paramType":"NUMBER","populationDescription":"Efficacy Analysis Set comprises of all participants who received at least one dose of study drug and have measurable disease as determined by the Investigator at baseline.","reportingStatus":"POSTED","timeFrame":"Up to 23 months","title":"Overall Response Rate (ORR) by the Investigator","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}